SEC Form 4 · accession 0000899243-19-000296
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence Otto Klein
Officer — Chief Business Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 3, 2019 · 4:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | Jan 2, 2019 | A | 20,000 | $29.87 | A | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $29.87 | Jan 2, 2019 | A | 20,000 | A | — | Jan 1, 2029 | Common Shares | 20,000 | 20,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one CRSP common share.
- F2The restricted stock units shall vest in full on January 2, 2021, subject to continued employment with the company.
- F325% of the option shall vest on January 2, 2020, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the final day of each month.